U.S. and China focused WuXi Healthcare Ventures Fund picked up $50 million from affiliated WuXi PharmaTech ($WX), the sprawling China-based biopharma CRO, according to documents filed with the U.S. Securities and Exchange Commission. The WuXi Healthcare Venture Fund II aims to raise a $250 million with the board at WuXi PharmaTech agreeing to act as the anchor and the extra $200 million seen from outside investors. The first WuXi Venture Fund started in 2014 with $50 million and has invested in more than a dozen life science companies. According to a Singapore-based life sciences investor not part of the fund, it has seen several profitable exits to date. SEC filing